Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.73 -0.01 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 241 - 260 ( 390 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FDA Pushes Back Selinexor PDUFA by Three Months to July 6; Could Be a Step in the Right Direction. PT Nudged to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Reports 4Q18 Results; Selinexor PDUFA April 6
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - AACR Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FDA AdCom Meeting Strikes Down Selinexor, Eyes Ahead to BOSTON
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ODAC Recommends the FDA Wait for Phase 3 BOSTON Data Before Deciding on Karyopharm?s Selinexor Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Bad Briefing Docs Arising, Trouble on the Way?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Model Update; Maintaining $30 PT, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ODAC Panel to Discuss Karyopharm?s Selinexor NDA Filing on February 26, 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Announces Selinexor MAA Submission to EMA in Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2018: Key Presentations Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Presents Strong Phase 2b STORM and SDd Data in MM at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Data for Phase 2b SADAL and Selinexor SPd at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Topline SADAL Paves Way for 1H19 sNDA filing in DLBCL, Potential AA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D